

Table 1. Comparison between responders and nonresponders for ES

Variable	Entire Cohort (N=31)	VGB Responders (N=16, 52%)	VGB Nonresponders (N=15, 48%)
<b>Sex, N (%)</b>			
Female	15 (48%)	9 (56%)	6 (40%)
Male	16 (52%)	7 (44%)	9 (60%)
<b>Ethnicity, N (%)</b>			
Black	6 (19%)	5 (31%)	1 (7%)
White	17 (55%)	8 (50%)	9 (60%)
Asian	2 (7%)	1 (6%)	1 (7%)
Hispanic	6 (19%)	2 (13%)	4 (26%)
<b>Gestational Age (weeks), median (range)</b>	36 (24-41)	37 (24-41)	37.5 (32-40)
<b>Age at diagnosis (mos), median (range)</b>	8.8 (2-36)	8.1 (5-36)	9.9 (2-36)
<b>Etiology, N (%)</b>			
Structural (acquired)	13 (42%)	8 (50%)	5 (33%)
Structural (innate)	2 (7%)	0	2 (13%)
Genetic/Metabolic	9 (29%)	2 (13%)	7 (47%)
Cryptogenic	6 (19%)	5 (31%)	1 (7%)
Idiopathic	1 (3%)	1 (6%)	0
<b>Development at diagnosis, N (%)</b>			
Abnormal	27 (87%)	13 (81%)	14 (93%)
Normal	4 (13%)	3 (19%)	1 (7%)
<b>Seizures before ES, N (%)</b>			
Yes	18 (58%)	9 (56%)	9 (60%)
No	13 (42%)	7 (44%)	6 (40%)
<b>Presence of AEDs before ES, N (%)</b>			
Yes	18 (58%)	9 (56%)	9 (60%)
No	13 (42%)	7 (44%)	6 (40%)

<b>Presence of AEDs post VGB wean, N (%)</b>			
Zero		4 (25%)	0
One		8 (50%)	2 (13%)
Two		2 (12.5%)	2 (13%)
Three		2 (12.5%)	5 (33%)
Four		0	3 (20%)
Five		0	3 (20%)
<b>Length of VGB treatment (mos)</b>	16.7 (3-60)	17.9 (1-60)	14.9 (2-48)
<b>VF complications, N (%)</b>			
Prior CVI			
No prior CVI	19 (61%)	8 (50%)	4 (27%)
VF loss	12 (39%)	8 (50%)	11 (73%)
	0	0	0
<b>Hypsarrhythmia on video EEG at diagnosis, N (%)</b>		8 (50%)	9 (60%)
		*Of these, only 1 had continued hypsarrhythmia but with resolution of ES at 3 months.	
<b>Abbreviations:</b>			
VGB: vigabatrin			
Mos: months			
ES: epileptic spasms			
AEDs: anti-epileptic drugs			
VF: visual field			